← Human Trials & Peer-Reviewed Studies
The effects of butyrate supplementation on glycemic control, lipid profile, blood pressure, nitric oxide level and glutathione peroxidase activity in type 2 diabetic patients: A randomized triple -blind, placebo-controlled trial.
Plain-language guide to PMID 35623879 (2022): randomized controlled trial of Glutathione in 2 patients, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 35623879
- Journal
- Clinical nutrition ESPEN
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Khosravi Z et al. (8 authors)
- DOI
- 10.1016/j.clnesp.2022.03.008
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glutathione in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.
This study aimed to investigate the effects of oral NaBut on metabolic parameters, blood pressure, and oxidative stress indices including glutathione peroxidase (GPx) and nitric oxide (NO) status in type 2 diabetic patients.
Who Took Part
The study group was 2 patients.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Glutathione and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Glutathione group a baseline to be compared against.
Serum concentrations of metabolic parameters, GPx, NO as well as blood pressure were assessed before and after the intervention.
What Was Measured
Topics PubMed links to this paper include Antioxidants, Blood Glucose, Blood Pressure, Butyrates, Cholesterol, LDL, Diabetes Mellitus, Type 2 and Dietary Supplements.
The authors tagged it with the keywords Butyric acid, Lipid metabolism and Oxidative stress.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Glutathione in 2 patients in people with low blood pressure and orthostatic hypotension.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Clinical nutrition ESPEN), a journal based in England.
More context: the Glutathione compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Glutathione: The body's main antioxidant.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.